The wider picture
The BA.3.2 variant, commonly referred to as the Cicada variant, was first identified in South Africa in November 2024. As a descendent of the BA.3 omicron subvariant that emerged in 2022, it has quickly gained attention due to its rapid spread across various countries. Currently, the Cicada variant has been detected in over 20 countries, with a notable rise in cases reported in the United States, where it has been observed in 25 states.
Health experts are closely monitoring the situation as the Cicada variant carries approximately 70 to 75 mutations in its spike protein. This significant number of mutations raises questions about its transmissibility and the effectiveness of existing vaccines. However, initial evidence suggests that the BA.3.2 variant does not cause more severe illness compared to earlier strains of COVID-19.
Common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms largely mirror those of previous COVID-19 strains, leading health authorities to emphasize the importance of staying vigilant.
Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” Most cases appear to be mild to moderate, resembling flu-like illness, particularly among vaccinated individuals. Experts highlight that most cases can be managed at home with rest and hydration.
Despite the presence of multiple mutations, vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. Health authorities continue to recommend that individuals stay up to date with vaccinations and take precautions in crowded settings to mitigate the spread of the variant.
As the Cicada variant spreads, health experts have noted that symptoms remain largely consistent with previous Omicron strains, with no new or unusual signs reported so far. However, there are concerns regarding the potential impact of the variant on vaccine efficacy due to its mutations. Some experts suggest that the current COVID-19 vaccines may not be as effective against it.
Health authorities are actively monitoring the BA.3.2 variant due to its rising presence. Observers anticipate that continued vigilance and adherence to public health guidelines will be crucial in managing the spread of this variant. As the situation evolves, details remain unconfirmed, and further updates will be essential for public awareness and safety.
